Figure 2.

Schematic illustration of the proposed model by which dual inhibition of enhancer of zeste homolog 1 and 2 (EZH1/2) eradicates AML leukemia stem cells (LSC). Quiescent LSC show PRC2‐mediated suppression of Cyclin D. Both genetic deletion of EZH1/2 and a novel EZH1/2 inhibitor induce cell cycle progression of quiescent LSC and differentiation to non‐quiescent LSC, resulting in eradication of quiescent LSC. These conditioned AML cells show a synergistic effect with conventional chemotherapy agents. PRC, polycomb repressive complexes